SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 2nd, 2024 • Cero Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 29, 2024, is by and among CERo Therapeutics Holdings, Inc. a Delaware corporation with offices located at 201 Haskins Way, Suite 230, South San Francisco, CA 94080 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 2nd, 2024 • Cero Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances)
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 28, 2024, is by and among CERo Therapeutics Holdings, Inc., a Delaware corporation with offices located at 201 Haskins Way, Suite 230, South San Francisco, CA 94080 (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).
CERO THERAPEUTIC HOLDINGS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for EMPLOYEEExecutive Employment Agreement • April 2nd, 2024 • Cero Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (the “Agreement”), made between CERO Therapeutic Holdings, Inc. (the “Company”) and Brian G. Atwood (the “Executive”) (collectively, the “Parties”), is effective as of March 28, 2024 (“Effective Date”).
CERo Therapeutics Holdings, Inc. March 28, 2024Cero Therapeutics Holdings, Inc. • April 2nd, 2024 • Biological products, (no disgnostic substances)
The Board of Directors (the “Board”) of CERo Therapeutics Holdings, Inc. (the “Company”) and its lead investors are excited about the prospect of your continued employment with a world-class team that we are building. This letter agreement (“Agreement”) sets forth the terms and conditions of your employment as of the closing of the Company’s business combination pursuant to that certain Business Combination Agreement, dated as of June 4, 2023, by and among the Company (then known as Phoenix Biotech Acquisition Corp.), CERo Therapeutics, Inc. (“CERo”), PBCE Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company, pursuant to which CERo became a wholly-owned subsidiary of the Company and the Company was renamed CERo Therapeutics Holdings, Inc., as amended by Amendment No. 1 thereto, dated as of March 28, 2024 (the “Effective Date”).
CERO THERAPEUTIC HOLDINGS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for EMPLOYEEExecutive Employment Agreement • April 2nd, 2024 • Cero Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (the “Agreement”), made between CERO Therapeutic Holdings, Inc. (the “Company”) and Charles R. Carter (the “Executive”) (collectively, the “Parties”), is effective as of March 26, 2024 (“Effective Date”).
